Q2 in Review: Pharma’s Dealmaking Surge, a Wave of FDA Approvals, and AI’s Deepening Footprint 

A PharmaShots Quarterly Analysis  Q2 was one of the most active quarters in recent memory for the pharmaceutical and biotech industry. Big Pharma leaned hard into M&A and licensing to refill pipelines, the FDA cleared a broad slate of new therapies, and AI-native partnerships continued to reshape how drugs get discovered. Below, we break down the quarter across four lenses: M&A, MedTech M&A, FDA approvals, and pharma dealmaking — with the numbers that put it all in context.  1. M&A: Big Pharma Goes Shopping — Again  Pharma M&A ran hot in Q2, with roughly 28 high-profile transactions totaling well over $107B in aggregate deal value (based on publicly disclosed figures; several deals carry undisclosed milestone components, so the real number is likely higher).  Biggest deals of the quarter:  Sun Pharma → Organon, ~$11.75B — the largest transaction of the period, signaling continued consolidation in the generics/branded hybrid space.  Merck KGaA → Bio-Techne, ~$11.3B  AbbVie → Apogee Therapeutics, ~$10.9B  GSK → Nuvalent, ~$10.6B  CVC Capital & Groupe Bruxelles Lambert → Recordati, €10.7B (~$12.4B) — a take-private via tender offer rather than a strategic pharma acquisition, underscoring continued private-equity appetite for durable pharma cash flows.  Standout trend – Eli Lilly’s acquisition spree: Lilly was the single most acquisitive company of the quarter, closing more than six separate deals (CrossBridge Bio, Kelonia Therapeutics, Ajax Therapeutics, and a $3.8B infectious-disease pipeline build spanning three acquisitions), collectively worth north of $12.4B. This positions Lilly as the quarter’s most aggressive pipeline-builder, spanning oncology, cell therapy, and infectious disease. Sector themes:  Oncology and rare/orphan disease dominated target selection (Apellis, Soleno, Vega, Kartos, Catalyst).  Neuroscience and CNS saw a notable cluster – UCB’s $1.15B move into regenerative epilepsy via Neurona, and its follow-on $2.2B acquisition of Candid Therapeutics, make UCB one of the quarter’s more active strategic consolidators alongside Lilly.  Cell and gene therapy picked up steam (Kelonia, Tubulis-based ADC technology via Gilead’s ~$5B deal).  European targets drew premium interest – KalVista (Chiesi, ~$1.9B), Recordati (CVC/GBL take-private), and Memo Therapeutics (Ipsen) all changed hands to non-domestic or PE acquirers, suggesting continued cross-border consolidation appetite in Europe.  2. MedTech M&A: Smaller Scale, Sharp AI/Diagnostics Focus MedTech M&A was quieter by dollar volume but notable for its focus on diagnostics and AI-enabled tools rather than devices:  Roche → PathAI, ~$1.05B – Roche doubling down on AI-powered pathology, reinforcing a broader industry pattern of diagnostics players acquiring AI capability rather than building it in-house.  CareDx → Naveris, ~$260M – extends CareDx’s transplant-monitoring franchise into oncology surveillance.  American Industrial Partners → Avanos Medical, ~$1.272B – a PE take-private of a device manufacturer.  Novanta → Riverpoint Medical, ~$1.45B – bolt-on in surgical/med-device components.  The Roche-PathAI deal is arguably the bellwether transaction here: it reflects a maturing thesis that AI-native diagnostics companies are now attractive, de-risked M&A targets rather than early-stage bets. 3. FDA Approvals: A Broad, Diverse Quarter The FDA cleared 14 new approvals across an unusually wide therapeutic spread – obesity, oncology, infectious disease, cardiovascular, ophthalmology, imaging, and anesthesia all saw new entrants:  Company Product Indication Eli Lilly Foundayo (orforglipron) Weight loss Merck Idvynso Virologically suppressed HIV-1 Arvinas / Pfizer Veppanu (vepdegestrant) ESR1-mutated breast cancer BeOne Medicines Beqalzi (sonrotoclax) R/R mantle cell lymphoma (accelerated) AstraZeneca Baxfendy (baxdrostat) Hard-to-control hypertension Gilead Hepcludex Chronic hepatitis delta virus (accelerated) AbbVie Decnupaz Blastic plasmacytoid dendritic cell neoplasm Wockhardt Zaynich Complicated UTI, incl. pyelonephritis Haisco Pharmaceutical Cypsedo Adult general anesthesia Shionogi Xocova PEP COVID-19 prevention Viridian Therapeutics Lumvoa (veligrotug-vvze) Thyroid eye disease Bayer Ambelvist (gadoquatrane) Contrast-enhanced MRI (CNS/body lesions) GSK / Spero Therapeutics Utebzi Complicated UTIs  What stands out:  Obesity remains the marquee category — Lilly’s Foundayo approval extends its GLP-1 dominance and lands amid intensifying orforglipron-class competition.  A cUTI cluster (Zaynich, Utebzi) suggests renewed FDA and industry focus on antibacterial resistance in urinary infections — a space that had seen thin approval activity in recent years.  Targeted oncology approvals (Veppanu, Beqalzi, Decnupaz) continue the shift toward precision, biomarker-defined indications rather than broad histology-based labels.  Two accelerated approvals (Beqalzi, Hepcludex) highlight continued FDA reliance on the accelerated pathway for rare and hard-to-treat conditions, even amid ongoing scrutiny of that pathway.  4. Pharma Deals: Licensing and AI-Native Collaborations Explode This was the busiest category by deal count, with more than 30 licensing, collaboration, and R&D partnerships.  Largest partnerships:  Pfizer / Innovent Biologics, ~$10.5B – a 12-program oncology collaboration, one of the largest biotech licensing deals of the year, deepening Pfizer’s China-sourced oncology pipeline strategy.  CytomX / Regeneron, ~$4B – expansion of a tumor-activated bispecific collaboration.  Haisco / Eli Lilly, ~$3.05B – a broad multi-therapeutic-area license and research pact.  Nurix Therapeutics / Roche, ~$3B – advancing bexobrutideg.  Regeneron / Parabilis Medicines, ~$2.3B – antibody-Helicon conjugates across multiple areas.  Profluent / Eli Lilly, ~$2.25B – AI-designed recombinases for genetic medicines.  Eli Lilly, again the standout: Beyond its acquisitions, Lilly inked separate licensing/collaboration deals this quarter (Abbisko, Ascidian, Haisco, Hanmi, Profluent, plus its earlier infectious-disease work), worth more than $12.5B in potential deal value. Combined with its M&A activity, Lilly’s total quarter-wide capital commitment across acquisitions and licensing approaches more than $25B by far the most active corporate development strategy of any company this quarter.  AI-native biotech partnerships are now mainstream, not novel:  Alnylam / Inceptive, ~$2B – AI-powered RNAi discovery.  Profluent / Eli Lilly, ~$2.25B – AI-designed recombinases.  XtalPi, >$400M – GPCR-targeted small-molecule discovery partnership.  These deals mark a clear shift: AI-drug-discovery partners are no longer signing small, exploratory deals – they’re commanding billion-dollar, milestone-heavy agreements comparable to traditional biotech licensing.  5. AI Funding & AI-in-Pharma: The Infrastructure Layer Matures  Two data points capture where AI-in-pharma is heading structurally, beyond individual drug-discovery partnerships:  Isomorphic Labs raised $2.1B in Series B funding to scale its AI drug-design engine and advance its own pipeline — one of the largest funding rounds ever for an AI-native drug discovery company, and a signal that investors are betting on platform-scale AI biotech, not just point partnerships.  Merck partnered with Google Cloud in a ~$1B deal to build an AI-enabled enterprise platform — a move up the value chain from discovery-stage AI tools toward enterprise-wide AI infrastructure, suggesting Big Pharma is now investing as much in AI operating infrastructure as in AI-derived molecules.  The Big Picture  Putting the quarter’s disclosed figures together:  Category Approx. Deal Count Approx. Total Value Pharma M&A >30 >$110B MedTech M&A >5 >$4B Pharma Licensing/Collaboration Deals >30 >$60B AI Funding & Infrastructure >5 >$4B Total disclosed activity >65 transactions ~$167B+  (Figures are approximate, based on publicly disclosed upfront/total deal values in the source data. Several deals include undisclosed milestone or royalty components not captured here.)  Three takeaways for the quarter:  Eli Lilly was the defining corporate story of Q2 – no other company came close in combined M&A and licensing volume, spanning obesity, oncology, cell therapy, infectious disease, and AI-driven genetic medicine.  Oncology and rare disease remain the primary M&A currency, but neuroscience (UCB, Angelini) and infectious disease (Lilly, Teva) saw a meaningful resurgence.  AI is no longer a side conversation – it showed up as a driver in drug discovery licensing (Alnylam, Profluent, XtalPi), M&A (Roche/PathAI), and enterprise infrastructure (Merck/Google Cloud), with Isomorphic Labs’ $2.1B raise underscoring investor conviction in AI-native platforms at scale.  This report is compiled from publicly announced deal terms and FDA approval disclosures for Q2. Deal values reflect disclosed upfront and/or total potential figures and may not account for all milestone or royalty terms. The post Q2 in Review: Pharma’s Dealmaking Surge, a Wave of FDA Approvals, and AI’s Deepening Footprint  appeared first on PharmaShots.